Jules Bordet

Type: Person
Name: Jules Bordet
First reported 17 hours ago - Updated 17 hours ago - 1 reports

Cancer drugs approved faster in the United States than in Europe or Canada

Source: © ESMOResearch presented at the ESMO 2014 Congress in Madrid highlighted variations in the time taken by regulatory agencies to approve new cancer drugsRegulatory agencies in the United States take less time to approve new cancer drugs than those ... [Published Pharmaceutical Journal - 17 hours ago]
Entities: Herceptin, Canada, Cancer
First reported 20 hours ago - Updated 20 hours ago - 1 reports

ESMO 2014 PIK3CA mutations blunt benefit of antiHER2 drugs in breast cancer

Patients with HER2 positive breast cancer derive less benefit from anti-HER2 drugs when they have PIK3CA mutations, according to Dr Evandro de Azambuja, medical director of the Br.E.A.S.T. Data Centre, Jules Bordet Institute in Brussels, Belgium.De.. ... [Published BioPortfolio - 20 hours ago]
First reported Sep 28 2014 - Updated Sep 29 2014 - 1 reports

Chemo and Radiotherapy Safe for Fetus During Later Pregnancy

MADRID — In utero exposure to chemotherapy appears to be safe, for the most part, when administered after the first trimester, according to data presented here at the European Society for Medical Oncology Congress 2014."Fear about the risks of chemotherapy ... [Published Diabetes Care - Sep 28 2014]
First reported Sep 27 2014 - Updated Sep 27 2014 - 1 reports

Oncologists slam regional variations in drug approvals, access

New studies which show that patients in some countries can wait years longer than those in others to access potentially life-saving cancer drugs demonstrate the need for better collaboration between doctors and health authorities globally, say researchers. ... [Published Pharma Times - Sep 27 2014]
First reported Sep 27 2014 - Updated Sep 27 2014 - 1 reports

Trastuzumab Trial Shows Fewer Cardiac Problems in HER2+ Breast Cancer Patients

TrastuzumabImage ToolsWhen administered for up to two years, the monoclonal antibody trastuzumab did not increase heart-related problems in otherwise healthy women with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer ... [Published Oncology Times - Sep 27 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 2 reports

FDA Proven Fastest In Study Of Cancer Drug Approval Times: Canada and Europe Years Slower In Some Cases

A recent survey revealed patients in some regions of the world wait years longer for new drugs to be approved compared to their counterparts in other regions. Two follow-up studies proved these results accurate and true, while also highlighting an on-the-ball ... [Published Medical Daily - Sep 26 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

ONLINE FIRST: HERA Trastuzumab Trial Shows Lower Risk of Cardiac Problems in HER2-Positive Breast Cancer Patients

BY KURT SAMSONWhen administered for up to two years, the monoclonal antibody trastuzumab did not increase heart-related problems in otherwise healthy women with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer after chemotherapy ... [Published Oncology Times - Aug 29 2014]

More Content

All (12) | News (12) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Cancer drugs approved faster in the United Stat... [Published Pharmaceutical Journal - 17 hours ago]
ESMO 2014 PIK3CA mutations blunt benefit of ant... [Published BioPortfolio - 20 hours ago]
ESMO 2014: PIK3CA mutations blunt benefit of an... [Published Ecancer Medicalscience - 21 hours ago]
Chemo and Radiotherapy Safe for Fetus During La... [Published Diabetes Care - Sep 28 2014]
Oncologists slam regional variations in drug ap... [Published Pharma Times - Sep 27 2014]
Trastuzumab Trial Shows Fewer Cardiac Problems ... [Published Oncology Times - Sep 27 2014]
FDA Proven Fastest In Study Of Cancer Drug Appr... [Published Medical Daily - Sep 26 2014]
Report Shows Discrepancies In Access to Cancer ... [Published PharmaceuticalProcessing - Sep 26 2014]
ONLINE FIRST: HERA Trastuzumab Trial Shows Lowe... [Published Oncology Times - Aug 29 2014]
Hormone Refractory Breast Cancer Global Clinica... [Published BioPortfolio - Mar 21 2014]
Volpara Solutions Launches Two Quantitative Bre... [Published PRWeb - Mar 07 2014]
arGEN-X begins phase Ib expansion cohorts with ... [Published PharmaBiz - Jan 14 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.